Dana-Farber Cancer Institute shared a post on LinkedIn:
“For years, RAS was considered one of the toughest targets in cancer research. In pancreatic cancer, that challenge is especially urgent.
New results in metastatic pancreatic cancer are highlighting the progress that’s possible when decades of basic science, translational research, clinical expertise, and patient partnership come together. In a global phase 3 trial, the RAS inhibitor daraxonrasib showed encouraging results, including longer median survival and improved quality of life for previously treated patients.
It’s an important milestone for a disease in which more than 90% of tumors are driven by RAS mutations – and a reminder that sustained investment in research can open doors once thought closed. Click the link below to read more.”
Other articles about RAS inhibitors on OncoDaily.